Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Paris
Clinical trial register · France

Clinical Trials in Paris, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Assistance Publique - Hôpitaux de Paris602 Novartis Pharmaceuticals68 Fondation Ophtalmologique Adolphe de Rothschild66 AstraZeneca64 Institut National de la Santé Et de la Recherche Médicale, France63 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Paris

64 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Toulouse
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,330
Angers, Caen, Montpellier, Paris, Poitiers
2026-09-15
Recruiting
AstraZeneca
Phase 3
1,072
Bordeaux, Paris, Strasbourg, Toulouse
2026-08-31
Recruiting
AstraZeneca
Phase 3
2,500
Bobigny, Colmar, Dijon, Paris, Pessac, Pierre-Bénite, Thionville, Toulouse
2026-08-19
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Bron, Marseille, Montpellier, Nantes, Paris, Pessac, Suresnes
2026-07-24
Recruiting
AstraZeneca
Phase 3
915
Bordeaux, Montpellier, Paris, Pierre-Bénite, Poitiers, Strasbourg
2026-07-16
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Poitiers, Toulouse
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Angers, Brest, Bron, Montpellier, Nice, Paris, Rennes, Tours
2026-06-11
Recruiting
AstraZeneca
Phase 3
245
Clermont-Ferrand, Lyon, Marseille, Paris, Pessac, Saint-Denis, Saint-Pierre, Toulon
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Lille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse
2026-02-23
Recruiting
AstraZeneca
Phase 3
1,100
Amiens, Avignon, Nîmes, Paris, Pau, Pierre-Bénite, Plerin SUR MER, Reims
2025-12-29
Recruiting
AstraZeneca
Phase 2
230
Lyon, Montpellier, Nantes, Nîmes, Paris, Tours
2025-12-10
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bordeaux, Dijon, Limoges, Marseille, Nantes, Nice, Paris
2025-11-24
Recruiting
AstraZeneca
Phase 2
435
Brest, Créteil, Marseille, Montpellier, Paris, Pessac, Strasbourg, Toulouse
2025-11-06
Recruiting
AstraZeneca
Phase 3
100
Clermont-Ferrand, La Roche-sur-Yon, Montpellier, Paris, Pierre-Bénite
2025-10-30
Recruiting
Tezspire Cardiac Events PASS
NCT06951867Cardiovascular Events, MACE
DrugTezepelumab
AstraZeneca
Observational
16,640
Paris
2025-09-15
Active, closed
AstraZeneca
Phase 3
212
Amiens, Bois-Guillaume, Bordeaux, Lille, Paris
2025-08-07
Recruiting
AstraZeneca
Phase 2
278
Avignon, Paris, Rennes, Saint-Herblain, Suresnes
2025-08-07
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Bron, Dijon, Marseille, Paris, Saint-Herblain
2025-06-10
Recruiting
AstraZeneca
Phase 1
72
Bordeaux, Montpellier, Nancy, Paris, Strasbourg, Toulouse
2025-05-01
Recruiting
AstraZeneca
Phase 3
600
Besançon, Bordeaux, Caen, Clermont-Ferrand, Lyon, Montpellier, Nice, Paris
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Brest, Lyon, Marseille, Montpellier, Paris, Pessac, Saint-Herblain
2025-03-25
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Clermont-Ferrand, Montpellier, Paris, Saint-Cloud, Villejuif
2025-01-30
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Montpellier, Paris, Pierre-Bénite, Rouen
2024-11-27
Active, closed
AstraZeneca
Phase 3
768
Bordeaux, Caen, Lille, Montpellier, Nantes, Paris, Pessac, Toulon Armees
2024-10-04
Recruiting
AstraZeneca
Observational
24,000
Paris
2024-09-30
Recruiting
AstraZeneca
Phase 3
788
Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain
2024-08-01
Active, closed
AstraZeneca
Phase 3
339
Bois-Guillaume, Dijon, Lyon, Montivilliers, Nantes, Paris, Poitiers, Toulouse
2024-06-29
Recruiting
AstraZeneca
Phase 3
240
Angers, Brest, Le Mans, Lille, Lyon, Paris, Reims, Rouen
2024-06-20
Recruiting
AstraZeneca
Phase 3
582
Angers, Marseille, Paris, Strasbourg
2024-04-29
Active, closed
AstraZeneca
Phase 2
142
La Tronche, Marseille, Montpellier, Mulhouse, Paris, Pessac, Poitiers, Toulouse
2024-02-22
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Caen, Marseille, Nantes, Paris, Pierre-Bénite, Toulouse
2023-12-29
Recruiting
AstraZeneca
Phase 3
625
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
2023-11-23
Active, closed
AstraZeneca
Phase 3
863
Brest, Créteil, Le Mans, Lille, Lyon, Marseille, Montpellier, Paris
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Bordeaux, Brest, Paris, Rennes, Strasbourg, Toulouse
2023-11-08
Recruiting
AstraZeneca
Phase 3
231
Brest, Bron, Créteil, Marseille, Paris, Rouen, Vandœuvre-lès-Nancy
2023-08-24
Active, closed
AstraZeneca
Phase 3
1,350
Brest, Créteil, Gleizé, Montpellier, Nîmes, Paris, Rouen, Saint-Quentin
2022-12-29
Active, closed
AstraZeneca
Phase 3
1,174
Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers
2022-11-28
Active, closed
AstraZeneca
Phase 3
594
Angers, Clamart, Clermont-Ferrand, Créteil, Lyon, Montpellier, Nantes, Paris
2022-09-15
Active, closed
AstraZeneca
Phase 2
194
Bobigny, Boulogne-Billancourt, Marseille, Paris, Pau, Pierre-Bénite, Poitiers, Vandœuvre-lès-Nancy
2022-08-11
Active, closed
AstraZeneca
Phase 3
341
Bobigny, Brest, Créteil, Dijon, Marseille, Paris, Poitiers, Rennes
2022-08-03
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen
2022-05-16
Active, closed
AstraZeneca
Phase 3
760
Angers, Clichy, Créteil, Montpellier, Nantes, Nice, Paris, Strasbourg
2022-03-28
Active, closed
AstraZeneca
Phase 3
1,035
Bordeaux, Brest, Clermont-Ferrand, Créteil, Montpellier, Paris, Rouen, Saint-Herblain
2022-03-25
Active, closed
AstraZeneca
Phase 3
791
Aix-en-Provence, Angers, Bobigny, Lille, Paris, Pau, Quimper, Saint-Grégoire
2022-02-18
Active, closed
AstraZeneca
Phase 3
363
Aurillac, Bordeaux, Marseille, Paris, Strasbourg, Toulouse
2022-02-15
Active, closed
AstraZeneca
Phase 3
1,157
Avignon, Besançon, Bordeaux, Caen, Le Mans, Montpellier, Nice, Paris
2021-04-26
Active, closed
AstraZeneca
Phase 3
1,012
Besançon, Bordeaux, Marseille, Montpellier, Nice, Paris, Pierre-Bénite, Quimper
2020-07-13
Active, closed
AstraZeneca
Phase 2
240
Paris, Vandœuvre-lès-Nancy
2020-04-22
Active, closed
AstraZeneca
Phase 3
140
Dijon, Marseille, Montpellier, Nantes, Paris, Suresnes, Toulouse
2019-10-29
Active, closed
AstraZeneca
Phase 3
923
Brest, Lyon, Marseille, Montpellier, Nice, Paris, Saint-Herblain, Villejuif
2019-06-25
Active, closed
AstraZeneca
Phase 3
810
Clichy, Dijon, Montpellier, Nice, Paris, Pessac, Poitiers
2019-04-16
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Lille, Marseille, Paris
2019-03-07
Active, closed
AstraZeneca
Phase 2
367
Dijon, Marseille, Nantes, Paris, Rennes
2019-01-09
Active, closed
AstraZeneca
Phase 3
1,407
Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain
2019-01-04
Active, closed
AstraZeneca
Phase 3
724
Bobigny, Clichy, Grenoble, Montpellier, Nice, Paris, Pessac, Toulouse
2018-11-30
Active, closed
AstraZeneca
Phase 2
528
Bordeaux, Nantes, Paris, Villejuif
2017-12-18
Active, closed
AstraZeneca
Phase 1/2
264
Bordeaux, Caen, Clermont-Ferrand, Dijon, Marseille, Nantes, Paris, Pierre Benit Cedex
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Bron, Lille, Limoges, Lyon, Paris
2015-10-21
Active, closed
AstraZeneca
Phase 3
510
Brest, Caen, Clermont-Ferrand, Dijon, Lille, Marseille, Paris, Pierre-Bénite
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Bordeaux, Caen, Lyon, Nantes, Paris, Pierre-Bénite, Saint-Cloud, Toulouse
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bordeaux, Caen, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy, Villejuif
2013-08-26
Rows per page Showing 1–64 of 64
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/paris

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 64 of those studies with a site in Paris that also match the filters currently applied.

How many clinical trials are recruiting in Paris?

29 of the 64 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 35 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Paris), 64 studies
PhaseStudiesRecruitingShare
Phase 3451870.3%
Phase 210515.6%
Phase 1/2537.8%
Observational324.7%
Phase 1111.6%

Most active sponsors

Lead sponsors with the most studies (Paris)
Lead sponsorStudiesRecruiting
AstraZeneca6429
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.